drugset / Trial / NCT01200342

Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma

NCT01200342

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research is to learn if the combination of Genasense (oblimersen), carboplatin, and paclitaxel (GCP) can help to control metastatic uveal melanoma. The safety of this combination will also be studied.

Timeline

Start
2010-12
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 6 unknown Intravenous
Subject Paclitaxel Small molecule 175 mg/m2 Intravenous
Subject oblimersen sodium Antisense oligonucleotide 900 mg Intravenous

Indications